Novo Nordisk aims for three new Dicerna drug candidates a year
Novo Nordisk’s ambition with the acquisition of Dicerna is to start three clinical studies a year, says Chief Scientific Officer Marcus Schindler at the company’s capital markets day.
by marketwire, translated by daniel pedersen
In fall of last year, Danish pharmaceutical firm Novo Nordisk acquired US-based Dicerna for USD 3.3bn. The purchase will bring in several drug candidates annually, says Marcus Schindler, chief scientific officer at Novo Nordisk, at the company’s capital markets day on Thursday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk acquires Dicerna for USD 3.3bn
For subscribers
Wegovy update on Novo Nordisk's capital markets day agenda
For subscribers
.jpg&w=384&q=75)
